Fennec Pharmaceuticals Investor Relations Material
Latest events
Q1 2025
Fennec Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Fennec Pharmaceuticals Inc
Access all reports
Fennec Pharmaceuticals Inc. is a specialized biopharmaceutical company primarily focused on developing treatments aimed at preventing ototoxicity (hearing loss) caused by platinum-based chemotherapy in pediatric cancer patients. Its flagship product, PEDMARK, represents a formulation of sodium thiosulfate designed to mitigate this side effect, catering to a niche yet critical aspect of pediatric oncology care. The company is headquartered in Research Triangle Park, North Carolina, and its shares are listed on the Nasdaq.
Latest articles
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
Ticker symbol
FENC
Country
🇺🇸 United States